Novel anthracyclines such as idarubicin, amrubicin, and menogaril offer potential advantages over conventional agents, including improved efficacy, reduced cardiotoxicity, and the possibility of oral administration.
No takes yet. Share an insight, caveat, or question.
Literature review data should not change practice; leaves open advantages of novel anthracyclines pending randomized trials.
Ueda et al. (1996) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: